Phase 2 trial (Lancet 2021) tested cagrilintide 0.3 mg through 4.5 mg/week as monotherapy and reported a clear dose-response, with 10.8% mean weight loss at 4.5 mg/week at 26 weeks
Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted
Read more Monday-Friday: 8am - 5pm Saturday: By appointment only Sunday: Closed Monday-Saturday: 8am - 4pm Walk-ins accepted 2026 Meraki Esthetique
Notably, participants consumed inadequate calories from carbohydrates, adequate calories from protein as a percentage of total calories (though critically insufficient in g/kg/day for muscle preservation), and excess calories from fat
In the form of a modern, sugar-free and calorie-free drink, they can be a practical everyday choice
Whether you're exploring injectable options like Wegovy or seeking oral solutions like Foundayo, each medication operates by reducing hunger and facilitating weight management